Skip to content
The Future Explorerby Benjamin Talin
Enablertechnological

Longevity & Health

Longevity & Healthspan Interventions

Medicines and therapies aimed at ageing itself rather than at each disease it brings, one at a time. One idea is to clear out worn-out 'zombie' cells that build up with age. One such drug was tested on 183 people with painful knees, and after twelve weeks it worked no better than a dummy injection. Every human result so far is early and small, and no regulator yet treats ageing as something a drug can be approved for.

Maturity

1/ 5
measured
BasisEvery human result is early and small, and a 183-patient Phase 2 trial of a senolytic missed its primary endpoint. No regulator treats ageing as something a drug can be approved for, and the trial built to change that has not started.SourceHickson et al., EBioMedicine 47:446–456 (Sep 2019); Justice et al., EBioMedicine 40:554–563 (Feb 2019); UNITY Biotechnology (17 Aug 2020); AFAR, TAME trial (accessed Sep 2026); Harrison et al., Nature 460 (Jul 2009)Vintage2009–2026
ReadinessCapability 1Deployment 1Absorption 1Bound bycapabilityTrendflat

Where it feeds in

4 megatrends in one forceweakest link

Where you have already met this

In 2020 Unity Biotechnology tested its lead senolytic - a drug meant to clear worn-out cells - in 183 people with painful knees. One injection into the joint. Twelve weeks later their pain had eased no more than on placebo. The company dropped the drug. The idea survived. The drug did not.

If this moved

If an ageing drug showed a clear benefit in a large human trial, the silver economy and the care economy - both held at 1 by this enabler alone - would be free to rise. Longevity and the healthspan gap would stay at 1 until brain-computer interfaces moved too. Fertility collapse would not move.

What to watch for

TAME enrolling its first participant. A regulator accepting a measure of biological age as a trial endpoint.

Not to be confused with

Geriatric medicine. Geriatrics treats the diseases of old age one by one as they appear; longevity medicine tries to slow the process that produces them.

What it is

Interventions aimed at the biology of ageing itself - senolytics, metabolic and cellular reprogramming approaches.

How it works

  1. 01Cells stop dividingDamage and stress push some cells into a permanent halt. They do not die; they stay.
  2. 02They poison the neighbourhoodThese senescent cells release inflammatory signals that harm the tissue around them, and they build up with age.
  3. 03A senolytic removes their defencesThe drug blocks the survival pathways senescent cells rely on, so they die while healthy cells are spared.
  4. 04The body clears themImmune cells remove the debris, and the inflammation should fall.
  5. 05Proving it is the hard partThe real endpoint is a longer, healthier life. Until a shorter measure is accepted, trials have to borrow a disease - a painful knee, a scarred lung - and test against that.

State of play

  • Rapamycin fed to mice from 600 days of age extended lifespan, measured at 90% mortality, by 14% in females and 9% in males (Harrison et al., Nature 460, Jul 2009).
  • In the first human senolytic pilot, 9 people with diabetic kidney disease took dasatinib and quercetin for three days; 11 days later they had fewer senescent cells in fat and skin (Hickson et al., EBioMedicine 47, Sep 2019).
  • In an open-label pilot, 14 people with idiopathic pulmonary fibrosis on the same drugs walked further and faster, but their lung function did not change (Justice et al., EBioMedicine 40, Feb 2019).
  • A single knee injection of the senolytic UBX0101 did no better than placebo on pain at 12 weeks in 183 patients with osteoarthritis, and the company did not take it further (UNITY Biotechnology, 17 Aug 2020).
  • The TAME trial of metformin has not launched: it still needs donor funding, 3,000 participants aged 65–79, and an FDA indication for ageing that does not exist (American Federation for Aging Research, accessed Sep 2026).

Why it matters

It targets the upstream driver of most age-related disease at once, rather than treating each disease separately. If it works even partially, the demographic and fiscal consequences are large.

  • It is the only enabler holding the silver economy and the care economy, both at 1. Those megatrends wait on this one.
  • It is the map's most overclaimed field. The mouse results are real. The human results are nine people, fourteen people, and one failed trial.
  • Lifespan without healthspan makes the ageing megatrends worse, not better. The distinction has to be held every time a result is announced.

What holds it back

No human efficacy yet

Nothing has yet shown that slowing ageing works in people, and the one sizeable senolytic trial in this record failed.

No indication to approve

Regulators approve drugs for diseases. Ageing is not one, so a trial has to be designed around something that is.

Trials take a lifetime

Without an accepted short-term marker of ageing, a trial has to wait for disease or death to show a difference.

Money for trials nobody can patent

TAME tests a cheap, off-patent drug and is waiting for donors to fund it.

Terms

Senescent cell
A cell that has stopped dividing for good but stays alive and releases inflammatory signals.
Senolytic
A drug that selectively kills senescent cells.
SASP
Senescence-associated secretory phenotype: the mix of inflammatory signals senescent cells release.
Epigenetic clock
An estimate of biological age from chemical marks on DNA.
Surrogate endpoint
A measurement a trial uses in place of the outcome that matters, because the real outcome takes too long to wait for.

Steepens

MegatrendWeightRole
Longevity and the Healthspan Gaplargeshared weakest link (with 1 other)
The Silver Economymoderateweakest link
The Care Economymoderateweakest link
Fertility Collapsemarginalmarginal: not counted as a weakest link

The gradient behaves like a sticky rubber band: it is pulled hardest toward the weakest enabler. Marginal links are shown but do not pull.

If this moved one step

Computed from the map as it stands: this score raised from 1 to 2, every other score unchanged. It is arithmetic, not a forecast.

Lifts the weakest link in

Tied as the weakest link

Here it shares the weakest spot with other enablers. Raising it alone leaves the weakest link where it is and lifts the gradient a little; the enablers it is tied with must move too.

What if it moved?

What would change the gradient

Conditional, not predictive. No dates, no probabilities.

  1. 01Validated biomarkers of ageing, which would shorten trials from decades to years
  2. 02Regulatory recognition of ageing as an indication
  3. 03Nothing on the enthusiasm side - funding is not the constraint here

Common misconception

That the field has demonstrated human results. Animal data is genuinely striking, human trials are early, and this is among the most overclaimed areas in this Compendium.

Talin, B. (2026). Longevity & Healthspan Interventions. The Future Explorer, dataset v0.4.0 (2026-11-16). https://explorer.talin.digital/e/longevity-and-healthspan-interventions/